Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Matthew Andrews's Stock Ratings
Jefferies Analyst
Matthew Andrews is an analyst at Jefferies. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/28/2025
Overall Average Return
86.1%
Smart Score
Overall Average Return Percentile
98th
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11/01/2023 | TGTX | Buy Now | TG Therapeutics | $36.73 | — | Matthew Andrews75% | — | Maintains | Buy | Get Alert |
| 02/06/2019 | CARA | Buy Now | Cara Therapeutics | — | — | Matthew Andrews75% | → $22 | Assumes | → Buy | Get Alert |
| 11/08/2018 | ALNA | Buy Now | Allena Pharmaceuticals | — | — | Matthew Andrews75% | → $22 | Assumes | → Buy | Get Alert |
| 09/13/2018 | CARA | Buy Now | Cara Therapeutics | — | — | Matthew Andrews75% | → $30 | Initiates | → Buy | Get Alert |
| 11/27/2017 | ALNA | Buy Now | Allena Pharmaceuticals | — | — | Matthew Andrews75% | → $22 | Initiates | → Buy | Get Alert |
| 09/12/2017 | CTIC | Buy Now | CTI BioPharma | — | — | Matthew Andrews75% | → $7.5 | Initiates | → Buy | Get Alert |
| 04/25/2017 | TGTX | Buy Now | TG Therapeutics | $36.73 | -37.38% | Matthew Andrews75% | → $23 | Initiates | → Buy | Get Alert |
| 03/21/2017 | GNMX | Buy Now | Aevi Genomic Medicine | — | — | Matthew Andrews75% | $10 → $2.5 | Downgrade | Buy → Hold | Get Alert |
